09.02.10
A new study published on the website of Nutrition, Metabolism & Cardiovascular Diseases and conducted by Dr. Peter Howe at the University of South Australia, demonstrates that DSM’s resVida resveratrol effectively improved flow mediated dilation (FMD) in humans. FMD is a bio-marker linked to the healthy functioning of the cardiovascular system.
In the double-blind, placebo-controlled trial, subjects took three different doses of resVida 99% trans-resveratrol (30, 90 and 270 mg). All doses were well absorbed into the blood stream in a dose dependent manner. The reactivity of blood vessels was then measured in the brachial artery. All three doses of resVida acutely and significantly increased the dilation of the brachial artery. The diameter of the artery was increased by 62% in the group who took 30 mg of resVida, while a 91% improvement was seen in the 270 mg group.
This is the first in a line of human clinical studies that DSM is working on for its resVida high-purity resveratrol ingredient. For further information: www.dsm.com